Abstract |
Clinical efficacy of skeletal myoblast (skMb) transplantation is controversial whether this treatment produces beneficial outcome in patients with dilated cardiomyopathy (DCM). Based on immunological tolerance between wild-type and DCM hamsters with the deletion of delta-sarcoglycan (SG) gene, skMb engraftment in TO-2 myocardium (3x10(5) cells in approximately 100mg heart) was verified by the donor-specific expression of delta-SG transgene constitutively produced throughout myogenesis. At 5 weeks after the transplantation, the cell rates expressing fast- myosin heavy chain (MHC) exceeded slow-MHC in delta-SG(+) cells. Fifteen weeks after (corresponding to approximately 12 years in humans), fast MHC(+) cells nullified, but the delta-SG(+) and slow MHC(+) cell number remained unaltered. These skMbs fused with host cardiomyocytes via connexin-43 and intercalated disc, modestly improving the hemodynamics without arrhythmia, when engrafted skMbs were sparsely disseminated in autopsied myocardium. These results provide us evidence that disseminating delivery of slow-MHC(+) myoblasts is promising for repairing DCM heart using histocompatible skeletal myoblasts in future.
|
Authors | Asaki Tezuka, Tomie Kawada, Mikio Nakazawa, Fujiko Masui, Satoshi Konno, Shin-Ichi Nitta, Teruhiko Toyo-Oka |
Journal | Biochemical and biophysical research communications
(Biochem Biophys Res Commun)
Vol. 369
Issue 1
Pg. 270-6
(Apr 25 2008)
ISSN: 1090-2104 [Electronic] United States |
PMID | 18047831
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Animals
- Cardiomyopathies
(pathology, surgery)
- Cell Differentiation
- Cell Proliferation
- Cells, Cultured
- Cricetinae
- Male
- Muscle, Skeletal
(pathology, transplantation)
- Myoblasts
(pathology, transplantation)
- Myocytes, Cardiac
(pathology)
- Regeneration
(physiology)
- Treatment Outcome
|